Clincosm LogoSign in Get a demo

Study to Assess PT010 in Adult and Adolescent Participants With Inadequately Controlled Asthma (LOGOS)

Sponsor
AstraZeneca (Industry)
Overall Status
Recruiting
CT.gov ID
NCT04609904
Collaborator
(none)
2,200
Enrollment
382
Locations
4
Arms
36.7
Anticipated Duration (Months)
5.8
Patients Per Site
0.2
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

This is a variable length study to evaluate the efficacy and safety of budesonide/glycopyrronium/formoterol inhaler in adults and adolescents with severe asthma inadequately controlled with standard of care.

Condition or Disease Intervention/Treatment Phase
  • Drug: BGF MDI 320/28.8/9.6 μg
  • Drug: BGF MDI 320/14.4/9.6 μg
  • Drug: BFF MDI 320/9.6 μg
  • Drug: BFF pMDI 320/9 μg
 Phase 3

Detailed Description

This is a randomized, double-blind, double dummy, parallel group, multicenter 24 to 52 week variable length study to assess the efficacy and safety of budesonide, glycopyrronium, and formoterol fumarate metered dose inhaler (MDI) relative to budesonide and formoterol fumarate MDI and Symbicort® pressurized MDI in adult and adolescent participants with inadequately controlled asthma. Approximately 2200 participants will be randomized globally.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
2200 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
A Randomized, Double-Blind, Double Dummy, Parallel Group, Multicenter Variable Length Study to Assess the Efficacy and Safety of PT010 Relative to PT009 and Symbicort® in Adult and Adolescent Participants With Inadequately Controlled Asthma
Actual Study Start Date :
Mar 1, 2021
Anticipated Primary Completion Date :
Mar 22, 2024
Anticipated Study Completion Date :
Mar 22, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: Budesonide, glycopyrronium, and formoterol fumarate (BGF) MDI 320/28.8/9.6 μg

BGF MDI 320/28.8/9.6 μg Budesonide, glycopyrronium, and formoterol fumarate (PT010) Metered Dose Inhaler (MDI)

Drug: BGF MDI 320/28.8/9.6 μg
Budesonide, glycopyrronium, and formoterol fumarate metered dose inhaler
Other Names:
  • BGF

    		•
    Experimental: BGF MDI 320/14.4/9.6 μg

    BGF MDI 320/14.4/9.6 μg Budesonide, glycopyrronium, and formoterol fumarate (PT010) Metered Dose Inhaler (MDI)

    Drug: BGF MDI 320/14.4/9.6 μg
    Budesonide, glycopyrronium, and formoterol fumarate metered dose inhaler
    Other Names:
  • BGF

    		•
    Active Comparator: Budesonide and formoterol fumarate (BFF) MDI 320/9.6 μg

    BFF MDI 320/9.6 μg (Experimental/Comparator) Budesonide and formoterol fumarate (PT009) Metered Dose Inhaler (MDI)

    Drug: BFF MDI 320/9.6 μg
    Budesonide and formoterol fumarate metered dose inhaler
    Other Names:
  • BFF

    		•
    Active Comparator: Symbicort®

    Budesonide/ formoterol fumarate pressurized metered dose inhaler (pMDI) 320/9 μg

    Drug: BFF pMDI 320/9 μg
    Budesonide/formoterol fumarate pressurized metered dose inhaler
    Other Names:
  • Symbicort®

    		•

    Outcome Measures

    Primary Outcome Measures

    1. Change from baseline in forced expiratory volume in 1 second (FEV1) area under the curve 0 to 3 hours (AUC0-3) at Week 24 [24 Weeks]

      Change from baseline in forced expiratory volume in 1 second (FEV1) area under the curve 0 to 3 hours (AUC0-3) at Week 24

    2. Rate of severe asthma exacerbations [Up to 52 Weeks]

      Primary end point(s) of Pooled Studies D5982C00007 and D5982C00008: Rate of severe asthma exacerbations

    Secondary Outcome Measures

    1. Change from baseline in morning pre-dose trough FEV1 at Week 24 [24 Weeks]

      Change from baseline in morning pre-dose trough FEV1 at Week 24

    2. Percentage of responders in Asthma Control Questionnaire (ACQ)-7 (≥0.5 decrease equals response) at Week 24 [24 Weeks]

      Percentage of responders in ACQ-7 (≥0.5 decrease equals response) at Week 24. Additional analysis will be conducted using pooled data from studies D5982C00007 and D5982C00008

    3. Percentage of responders in ACQ-5 (≥0.5 decrease equals response) at Week 24 [24 Weeks]

      Percentage of responders in ACQ-5 (≥0.5 decrease equals response) at Week 24. Additional analysis will be conducted using pooled data from studies D5982C00007 and D5982C00008

    4. Percentage of responders in the Asthma Quality of Life Questionnaire for 12 years and older (AQLQ +12) (≥0.5 increase equals response) at Week 24 [24 Weeks]

      Percentage of responders in the Asthma Quality of Life Questionnaire for 12 years and older (AQLQ +12) (≥0.5 increase equals response) at Week 24. Additional analysis will be conducted using pooled data from studies D5982C00007 and D5982C00008

    5. Percentage of responders in the St. George's Respiratory Questionnaire (SGRQ) (≥4.0 unit decrease equals response) at Week 24 [24 Weeks]

      Percentage of responders in the St. George's Respiratory Questionnaire (SGRQ) (≥4.0 unit decrease equals response) at Week 24

    6. Onset of action on Day 1: Absolute change in FEV1 at 5 minutes on Day 1 [Day 1]

      Onset of action on Day 1: Absolute change in FEV1 at 5 minutes on Day 1

    7. Time to first severe asthma exacerbation [Up to 52 Weeks]

      Secondary end point(s) of Pooled Studies D5982C00007 and D5982C00008: Time to first severe asthma exacerbation

    8. Rate of moderate/severe asthma exacerbations [Up to 52 Weeks]

      Secondary end point(s) of Pooled Studies D5982C00007 and D5982C00008: Rate of moderate/severe asthma exacerbations

    9. Time to first moderate/severe asthma exacerbation [Up to 52 Weeks]

      Secondary end point(s) of Pooled Studies D5982C00007 and D5982C00008: Time to first moderate/severe asthma exacerbation

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    12 Years to 80 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:

    1. 12 to 80 years of age, male and female, BMI <40 kg/m2; females must be not of childbearing potential or using a form of highly effective birth control.

    2. Documented history of physician-diagnosed asthma > and/or = 1 year prior to V1.

    3. Regularly using a stable daily ICS/LABA regimen (including a stable ICS dose) with medium-to-high ICS doses for at least 4 weeks prior to V1.

    4. ACQ-7 total score ≥1.5 at Visits 1, 3, and 5 (pre-randomization).

    5. FEV1 % (assessed as an average of the 60 and 30 minute pre-dose assessments) predicted normal at V1, 2, 3, 4, and 5 (pre-randomization)

    • Participants > and/or = 18 years of age: < 80%

    • Participants 12 to <18 years of age: < 90%

    1. FEV1 post-albuterol at V2 or V3 (if repeat needed). • Participants > and/or = 18 years of age: Increase > and/or = 12% and > and/or = 200 mL.

    • Participants 12 to <18 years of age: Increase =12% either in the 12 months prior to Visit 1 or at Visit 2, or at Visit 3.

    • Note: Reversibility testing is still required at Visit 2 and/or Visit 3, even if the patient has documented historical reversibility reported in the 12 months prior to Visit 1.

    1. Willing and, in the opinion of the Investigator, able to adjust current asthma therapy, as required by the protocol.

    2. Demonstrate acceptable MDI/pMDI administration technique.

    3. Received no asthma medication other than run-in BFF MDI BID and albuterol as needed during screening (except for allowed medications as defined in Table 9 and systemic corticosteroid or ICS for the treatment of an asthma exacerbation).

    4. eDiary 14-day compliance ≥70% during screening (defined as completing the daily eDiary for any 10 mornings and any 10 evenings and answering "Yes" to taking 2 puffs of run-in BFF MDI for any 10 mornings and 10 evenings in the last 14 days prior to randomization).

    5. No respiratory infection in the 4 weeks prior to randomization, or asthma exacerbation treated with systemic corticosteroid and/or additional ICS treatment in the 4 weeks prior to randomization.

    Exclusion Criteria:
    1. Completed treatment for respiratory infection or asthma exacerbation with systemic corticosteroids within 4 weeks of V1.

    2a. Participants where, in the opinion of the Investigator, treatment with biological therapy for asthma would be appropriate.

    2b. Any marketed or investigational biologics within 3 months or 5 halflives of V1, whichever is longer and must not be used during study duration.

    1. Current smokers, former smokers with >10 pack-years history, or former smokers who stopped smoking <6 months prior to V1 (including all forms of tobacco, e-cigarettes or other vaping devices, and marijuana).

    2. Current evidence of COPD.

    5a. Oral and IV corticosteroid use (any dose) within 4 weeks of V1.

    5b. Use of systemic corticosteroids for any other reason except for the acute treatment of severe asthma exacerbation is prohibited for the duration of the study.

    5c. Depot corticosteroid use for any reason within 12 months of V1.

    1. Use of LAMA, either alone or as part of an inhaled combination therapy, in the 12 weeks prior to Visit 1.

    2. Use of oral b2-agonist within 3 months of V1.

    3. Use of any immunomodulators or immunosuppressive medication within 3 months or 5 half-lives, whichever is longer, and must not be used during the study duration.

    4. Narrow angle glaucoma not adequately treated and/or change in vision that may be relevant, in the opinion of the Investigator, within 3 months of Visit 1.

    5. Life-threatening asthma defined as a history of significant asthma episode(s) requiring intubation associated with hypercapnia, respiratory arrest, hypoxic seizures, or asthma-related syncopal episode(s).

    6. Hospitalization for asthma within 2 months of Visit 1.

    7. Known history of drug or alcohol abuse within 12 months of Visit 1.

    8. Regular use of a nebulizer or a home nebulizer for receiving asthma medications.

    9. Using any herbal products by inhalation or nebulizer within 4 weeks of Visit 1 and does not agree to stop during the study duration.

    10. Participation in another clinical study with an Investigational Product.

    11. Participants with a known hypersensitivity to beta2-agonists, corticosteroids, anticholinergics, or any component of the MDI or pMDI.

    12. Study Investigators, sub-Investigators, coordinators, and their employees or immediate family members.

    13. For women only - currently pregnant (confirmed with positive highly sensitive pregnancy test), breast-feeding, or planned pregnancy during the study or not using acceptable contraception measures, as judged by the Investigator.

    Please refer to the study protocol for the complete inclusion and exclusion criteria list

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Research Site Muscle Shoals Alabama United States 35661
    2 Research Site Chandler Arizona United States 85224
    3 Research Site Phoenix Arizona United States 85051
    4 Research Site Tucson Arizona United States 85741
    5 Research Site Conway Arkansas United States 72032
    6 Research Site Hot Springs National Park Arkansas United States 71913
    7 Research Site Little Rock Arkansas United States 72205
    8 Research Site Little Rock Arkansas United States 72212
    9 Research Site North Little Rock Arkansas United States 72117
    10 Research Site Anaheim California United States 92805
    11 Research Site Bakersfield California United States 93301
    12 Research Site Carlsbad California United States 92009
    13 Research Site Escondido California United States 92025
    14 Research Site Huntington Beach California United States 92647
    15 Research Site Huntington Beach California United States 92647
    16 Research Site Inglewood California United States 90303
    17 Research Site Lancaster California United States 93534
    18 Research Site Long Beach California United States 90806
    19 Research Site Long Beach California United States 90806
    20 Research Site Los Angeles California United States 90033
    21 Research Site Los Angeles California United States 90048
    22 Research Site Mission Viejo California United States 92691
    23 Research Site North Hollywood California United States 91606
    24 Research Site Northridge California United States 91324
    25 Research Site Orange California United States 92868
    26 Research Site Palmdale California United States 93550
    27 Research Site Sacramento California United States 95825
    28 Research Site San Diego California United States 92103
    29 Research Site San Diego California United States 92120
    30 Research Site San Jose California United States 95117
    31 Research Site Colorado Springs Colorado United States 80910
    32 Research Site Newark Delaware United States 19713
    33 Research Site Boca Raton Florida United States 33487
    34 Research Site Clearwater Florida United States 33756
    35 Research Site Clearwater Florida United States 33765
    36 Research Site Davenport Florida United States 33896
    37 Research Site Kissimmee Florida United States 34746
    38 Research Site Lakeland Florida United States 33813
    39 Research Site North Port Florida United States 34287
    40 Research Site Orlando Florida United States 32807
    41 Research Site Saint Petersburg Florida United States 33704
    42 Research Site Tampa Florida United States 33615
    43 Research Site Acworth Georgia United States 30101
    44 Research Site Alpharetta Georgia United States 30022
    45 Research Site Atlanta Georgia United States 30322
    46 Research Site Atlanta Georgia United States 30342
    47 Research Site Buford Georgia United States 30518
    48 Research Site Fayetteville Georgia United States 30214
    49 Research Site Hinesville Georgia United States 31313
    50 Research Site Newnan Georgia United States 30265
    51 Research Site Peachtree City Georgia United States 30269
    52 Research Site Snellville Georgia United States 30078
    53 Research Site Stone Mountain Georgia United States 30083
    54 Research Site Boise Idaho United States 83706
    55 Research Site Chicago Illinois United States 60621
    56 Research Site Chicago Illinois United States 60641
    57 Research Site Normal Illinois United States 61761
    58 Research Site Evansville Indiana United States 47715
    59 Research Site Marrero Louisiana United States 70072
    60 Research Site Zachary Louisiana United States 70791
    61 Research Site Baltimore Maryland United States 21224
    62 Research Site White Marsh Maryland United States 21162
    63 Research Site Fall River Massachusetts United States 02723
    64 Research Site North Dartmouth Massachusetts United States 02747
    65 Research Site Caro Michigan United States 48723
    66 Research Site Farmington Hills Michigan United States 48336
    67 Research Site Rochester Michigan United States 48307
    68 Research Site Troy Michigan United States 48085
    69 Research Site Chesterfield Missouri United States 63017
    70 Research Site Saint Louis Missouri United States 63141
    71 Research Site Warrensburg Missouri United States 64093
    72 Research Site Brick New Jersey United States 08724
    73 Research Site Albuquerque New Mexico United States 87102
    74 Research Site Bronx New York United States 10459
    75 Research Site Bronx New York United States 10461
    76 Research Site Bronx New York United States 10468
    77 Research Site Brooklyn New York United States 11236
    78 Research Site Corning New York United States 14830
    79 Research Site New York New York United States 10036
    80 Research Site North Massapequa New York United States 11758
    81 Research Site Port Jefferson New York United States 11766
    82 Research Site Rochester New York United States 14642
    83 Research Site Charlotte North Carolina United States 28210
    84 Research Site Elizabeth City North Carolina United States 27909
    85 Research Site Greensboro North Carolina United States 27408
    86 Research Site High Point North Carolina United States 27262
    87 Research Site Huntersville North Carolina United States 28078
    88 Research Site Monroe North Carolina United States 28112
    89 Research Site Oklahoma City Oklahoma United States 73106
    90 Research Site Portland Oregon United States 97202
    91 Research Site Jenkintown Pennsylvania United States 19046
    92 Research Site Philadelphia Pennsylvania United States 19107
    93 Research Site Philadelphia Pennsylvania United States 19140
    94 Research Site Pittsburgh Pennsylvania United States 15212
    95 Research Site Johnston Rhode Island United States 02919
    96 Research Site Rock Hill South Carolina United States 29732
    97 Research Site Spartanburg South Carolina United States 29303
    98 Research Site Hendersonville Tennessee United States 37075
    99 Research Site Knoxville Tennessee United States 37909
    100 Research Site Cedar Park Texas United States 78613
    101 Research Site Conroe Texas United States 77384
    102 Research Site Corsicana Texas United States 75110
    103 Research Site Dallas Texas United States 75230
    104 Research Site Denison Texas United States 75020
    105 Research Site Denison Texas United States 75020
    106 Research Site Houston Texas United States 77004
    107 Research Site Houston Texas United States 77074
    108 Research Site Lewisville Texas United States 75067
    109 Research Site McAllen Texas United States 78504
    110 Research Site McKinney Texas United States 75069
    111 Research Site McKinney Texas United States 75071
    112 Research Site McKinney Texas United States 75071
    113 Research Site Mesquite Texas United States 75149
    114 Research Site North Richland Hills Texas United States 76180
    115 Research Site Pearland Texas United States 77584
    116 Research Site Pflugerville Texas United States 78660
    117 Research Site Pharr Texas United States 78577
    118 Research Site Plano Texas United States 75093
    119 Research Site San Antonio Texas United States 78229
    120 Research Site Sugar Land Texas United States 77478
    121 Research Site Sugar Land Texas United States 77479
    122 Research Site Abingdon Virginia United States 24210
    123 Research Site Burke Virginia United States 22015
    124 Research Site Williamsburg Virginia United States 23188
    125 Research Site Milwaukee Wisconsin United States 53226
    126 Research Site Milwaukee Wisconsin United States 53228
    127 Research Site Bludenz Austria 6700
    128 Research Site Feldbach Austria A-8330
    129 Research Site Linz Austria 4020
    130 Research Site Thalheim Austria 4600
    131 Research Site Botucatu Brazil 18618-970
    132 Research Site Porto Alegre Brazil 9002-060
    133 Research Site Porto Alegre Brazil 90430-001
    134 Research Site Porto Alegre Brazil 90610-000
    135 Research Site Porto Alegre Brazil 91350-200
    136 Research Site Santo Andre Brazil 09080-110
    137 Research Site Sorocaba Brazil 18040-425
    138 Research Site São Paulo Brazil 05403-000
    139 Research Site Uberlandia Brazil 38411-186
    140 Research Site Anhui China 230061
    141 Research Site Baotou China 014010
    142 Research Site Beijing China 100020
    143 Research Site Beijing China
    144 Research Site Changchun China
    145 Research Site Changsha China 410005
    146 Research Site Changsha China 410008
    147 Research Site Changsha China 430033
    148 Research Site Chongqing China 400010
    149 Research Site Chongqing China 400038
    150 Research Site Fuzhou China 350025
    151 Research Site Gongguan China
    152 Research Site Guangzhou China 510062
    153 Research Site Guangzhou China 510120
    154 Research Site Guangzhou China 510180
    155 Research Site Guangzhou China 510280
    156 Research Site Guangzhou China 510630
    157 Research Site Guangzhou China
    158 Research Site Guiyang China 550002
    159 Research Site Haikou China 570208
    160 Research Site Haikou China 570311
    161 Research Site Hangzhou China 310005
    162 Research Site Hangzhou China 310006
    163 Research Site Hangzhou China 310009
    164 Research Site Hefei China 230000
    165 Research Site Hefei China 230022
    166 Research Site Hohhot China 010017
    167 Research Site Huai'an China 223300
    168 Research Site Huizhou China 516001
    169 Research Site Jinan China 250001
    170 Research Site Jinan China 250021
    171 Research Site Jinan China 250117
    172 Research Site Jinhua China 321000
    173 Research Site Kunming China 650032
    174 Research Site Lanzhou China 730000
    175 Research Site Luoyang China 471003
    176 Research Site Nan Chong China 637000
    177 Research Site Nanchang China 330006
    178 Research Site Nanjing China 210006
    179 Research Site Nanjing China 210008
    180 Research Site Nanjing China 210009
    181 Research Site Nanjing China 210029
    182 Research Site Nanning China 530021
    183 Research Site Qingdao China 266000
    184 Research Site Shanghai China 2000127
    185 Research Site Shanghai China 200025
    186 Research Site Shanghai China 200032
    187 Research Site Shanghai China 200065
    188 Research Site Shanghai China 200080
    189 Research Site Shanghai China 200092
    190 Research Site Shanghai China 200233
    191 Research Site Shanghai China 200240
    192 Research Site Shanghai China 200433
    193 Research Site Shanghai China 201199
    194 Research Site Shangrao China 334000
    195 Research Site Shantou China 515041
    196 Research Site Shaoxing China 312000
    197 Research Site Shengyang China 110004
    198 Research Site Shenyang China 110001
    199 Research Site Shenyang China 110015
    200 Research Site Shenzhen China 518020
    201 Research Site Shenzhen China 518036
    202 Research Site Shenzhen China 518039
    203 Research Site Shihezi China 830000
    204 Research Site Shijiazhuang China 50051
    205 Research Site Tai'an China 271000
    206 Research Site Taiyuan China 030001
    207 Research Site Taizhou China 318020
    208 Research Site Urumqi China 830054
    209 Research Site Wenzhou China 325027
    210 Research Site Wuhan China 430010
    211 Research Site Wuhan China 430030
    212 Research Site Wuhu China 241000
    213 Research Site Xi'an China 710004
    214 Research Site Xian China 710061
    215 Research Site Xuzhou China 221000
    216 Research Site Xuzhou China 221009
    217 Research Site Xuzhou China
    218 Research Site Yangzhou China 225001
    219 Research Site Yinchuan China 750001
    220 Research Site Yinchuan China 750004
    221 Research Site Zhanjiang China 524001
    222 Research Site Zhengzhou City China 450000
    223 Research Site Zhengzhou China 450000
    224 Research Site Zhuji China
    225 Research Site Bogota Colombia 110221
    226 Research Site Cartagena Colombia 130013
    227 Research Site Manizales Colombia 17001
    228 Research Site Medellin Colombia 050034
    229 Research Site Rionegro Colombia 54040
    230 Research Site San Gil Colombia 684031
    231 Research Site San José Costa Rica 10103
    232 Research Site Santa Ana Costa Rica 10903
    233 Research Site Brandys nad Labem Czechia 250 01
    234 Research Site Jindrichuv Hradec Czechia 377 01
    235 Research Site Liberec Czechia 460 01
    236 Research Site Lovosice Czechia 410 02
    237 Research Site Mlada Boleslav Czechia 293 01
    238 Research Site Novy Bor Czechia 473 01
    239 Research Site Praha 9 Czechia 190 00
    240 Research Site Rokycany Czechia 337 22
    241 Research Site Strakonice Czechia 38601
    242 Research Site Teplice Czechia 415 01
    243 Research Site Varnsdorf Czechia 407 47
    244 Research Site Bamberg Germany 96049
    245 Research Site Berlin Germany 10119
    246 Research Site Berlin Germany 10367
    247 Research Site Berlin Germany 10717
    248 Research Site Berlin Germany 12159
    249 Research Site Berlin Germany 12203
    250 Research Site Berlin Germany 13057
    251 Research Site Berlin Germany 13187
    252 Research Site Berlin Germany 13187
    253 Research Site Darmstadt Germany 64283
    254 Research Site Duisburg Germany 47057
    255 Research Site Frankfurt am Main Germany 60596
    256 Research Site Frankfurt/Main Germany 60389
    257 Research Site Frankfurt Germany 60596
    258 Research Site Geesthacht Germany 21502
    259 Research Site Hannover Germany D-30173
    260 Research Site Koblenz Germany 56068
    261 Research Site Leipzig Germany 04103
    262 Research Site Leipzig Germany 04207
    263 Research Site Leipzig Germany 04299
    264 Research Site Leipzig Germany 04357
    265 Research Site Mainz Germany 55128
    266 Research Site Marburg Germany 35037
    267 Research Site München-Pasing Germany 81241
    268 Research Site Alexandroupolis Greece 68100
    269 Research Site Athens Greece 11525
    270 Research Site Athens Greece 11527
    271 Research Site Athens Greece 11527
    272 Research Site Athens Greece 12462
    273 Research Site Athens Greece 17562
    274 Research Site Exohi Thessaloniki Greece 57010
    275 Research Site Heraklion Greece 71110
    276 Research Site Ioannina Greece 45500
    277 Research Site Patras Greece 26500
    278 Research Site Thessaloniki Greece 56429
    279 Research Site Thessaloniki Greece 57010
    280 Research Site Ashqelon Israel 7830604
    281 Research Site Beer Sheva Israel 84101
    282 Research Site Haifa Israel 31096
    283 Research Site Haifa Israel 34362
    284 Research Site Jerusalem Israel 9103102
    285 Research Site Jerusalem Israel 9112001
    286 Research Site Kfar Saba Israel 4428164
    287 Research Site Petach-Tikva Israel 4920235
    288 Research Site Petah Tikva Israel 4920235
    289 Research Site Ramat-Gan Israel 52621
    290 Research Site Rehovot Israel 76100
    291 Research Site Tel Aviv Israel 6423906
    292 Research Site Ciudad de Mexico Mexico 6700
    293 Research Site Culiacán Mexico 80200
    294 Research Site Durango Mexico 43080
    295 Research Site Guadalajara Mexico 44200
    296 Research Site Mazatlán Mexico 82000
    297 Research Site Monterrey Mexico 64620
    298 Research Site Monterrey Mexico 64710
    299 Research Site Monterrey Mexico 64718
    300 Research Site Puebla Mexico 72190
    301 Research Site Veracruz Mexico 91910
    302 Research Site Villahermosa Mexico 86035
    303 Research Site Amadora Portugal 2720-276
    304 Research Site Barcelos Portugal 4750-333
    305 Research Site Braga Portugal 4710
    306 Research Site Guarda Portugal 6300-035
    307 Research Site Guimaraes Portugal 4835-044
    308 Research Site Lisboa Portugal 1998-018
    309 Research Site Matosinhos Portugal 4454-509
    310 Research Site Vila Nova de Gaia Portugal 4434-502
    311 Research Site Ponce Puerto Rico 00717
    312 Research Site Ponce Puerto Rico 00780
    313 Research Site Chelyabinsk Russian Federation 454106
    314 Research Site Izhevsk Russian Federation 426035
    315 Research Site Kazan Russian Federation 420008
    316 Research Site Kemerovo Russian Federation 650002
    317 Research Site Kirov Russian Federation 610014
    318 Research Site Moscow Russian Federation 115522
    319 Research Site Moscow Russian Federation 125284
    320 Research Site Omsk Russian Federation 644033
    321 Research Site Penza Russian Federation 440067
    322 Research Site Perm Russian Federation 614000
    323 Research Site Saint Petersburg Russian Federation 194354
    324 Research Site Saint Petersburg Russian Federation 195257
    325 Research Site Saratov Russian Federation 410012
    326 Research Site Saratov Russian Federation 410028
    327 Research Site Saratov Russian Federation 410053
    328 Research Site Tomsk Russian Federation 634050
    329 Research Site Ulyanovsk Russian Federation 432009
    330 Research Site Ar Riyāḑ Saudi Arabia 11426
    331 Research Site Jeddah Saudi Arabia 21423
    332 Research Site Jeddah Saudi Arabia 22252
    333 Research Site Makkah Saudi Arabia 24246
    334 Research Site Riyadh Saudi Arabia 1121
    335 Research Site Riyadh Saudi Arabia 12231
    336 Research Site Riyadh Saudi Arabia 12233
    337 Research Site Riyadh Saudi Arabia 12713
    338 Research Site Bojnice Slovakia 972 01
    339 Research Site Kezmarok Slovakia 060 01
    340 Research Site Kosice Slovakia 04022
    341 Research Site Levice Slovakia 934 01
    342 Research Site Nove Zamky Slovakia 940 01
    343 Research Site Nove Zamky Slovakia 94001
    344 Research Site Poprad Slovakia 058 01
    345 Research Site Ruzomberok Slovakia 034 26
    346 Research Site Surany Slovakia 94201
    347 Research Site Topolcany Slovakia 95501
    348 Research Site Bellville South Africa 7530
    349 Research Site Bloemfontein South Africa 9301
    350 Research Site Cape Town South Africa 7570
    351 Research Site Cape Town South Africa 7700
    352 Research Site Cape Town South Africa 7764
    353 Research Site Durban South Africa 4001
    354 Research Site Durban South Africa 4091
    355 Research Site Durban South Africa 4093
    356 Research Site Durban South Africa 4450
    357 Research Site Johannesburg South Africa 2001
    358 Research Site Johannesburg South Africa 2013
    359 Research Site Lenasia Ext8 South Africa 1820
    360 Research Site Lenasia South South Africa 1835
    361 Research Site Panorama South Africa 7500
    362 Research Site Pretoria South Africa 0186
    363 Research Site Umkomaas South Africa 4170
    364 Research Site Lund Sweden 222 22
    365 Research Site Stockholm Sweden 111 20
    366 Research Site Uppsala Sweden 75237
    367 Research Site Adana Turkey 01330
    368 Research Site Ankara Turkey 06280
    369 Research Site Ankara Turkey 06
    370 Research Site Istanbul Turkey 34010
    371 Research Site Istanbul Turkey 34098
    372 Research Site İstanbul Turkey 34844
    373 Research Site Izmir Turkey 35110
    374 Research Site Manisa Turkey 45030
    375 Research Site Mersin Turkey 33079
    376 Research Site Pamukkale Turkey 20070
    377 Research Site Blackpool United Kingdom FY3 7EN
    378 Research Site Bradford United Kingdom BD9 6RJ
    379 Research Site Corby United Kingdom NN17 2UR
    380 Research Site Hull United Kingdom HU16 5JQ
    381 Research Site Leicester United Kingdom LE5 4LJ
    382 Research Site Rhyl United Kingdom LL18 1DA

    Sponsors and Collaborators

    • AstraZeneca

    Investigators

    • Principal Investigator: Robert Wise, MD, Johns Hopkins University

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    AstraZeneca
    ClinicalTrials.gov Identifier:
    NCT04609904
    Other Study ID Numbers:
    • D5982C00008
    • 2020-001521-31
    First Posted:
    Oct 30, 2020
    Last Update Posted:
    Aug 17, 2022
    Last Verified:
    Aug 1, 2022
    Individual Participant Data (IPD) Sharing Statement:
    Yes
    Plan to Share IPD:
    Yes
    Studies a U.S. FDA-regulated Drug Product:
    Yes
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:
    Asthma
    Budesonide, Formoterol Fumarate Drug Combination

    Study Results

    No Results Posted as of Aug 17, 2022